Picture loading failed.

Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vibostolimab is a TIGIT-targeting (T-cell immunoreceptor with Ig) antibody is being developed by Merck Sharp & Dohme for the treatment of solid tumours such as non-small cell lung cancer, malignant melanoma.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-620-1mg 1mg 3090
GMP-Bios-ab-620-10mg 10mg Inquiry
GMP-Bios-ab-620-100mg 100mg Inquiry
GMP-Bios-ab-620-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vibostolimab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody
INN Name Vibostolimab
TargetTIGIT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesMerck
Conditions Approvedna
Conditions ActiveSolid tumours;Non-small cell lung cancer;Malignant melanoma
Conditions Discontinuedna
Development Techna